4.6 Article

Nanofibrous PCL-Based Human Trabecular Meshwork for Aqueous Humor Outflow Studies

Journal

ACS BIOMATERIALS SCIENCE & ENGINEERING
Volume 9, Issue 11, Pages 6333-6344

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsbiomaterials.3c01071

Keywords

trabecular meshwork; electrospinning; polycaprolactone; outflow system; glaucoma; drug screening

Ask authors/readers for more resources

The researchers developed an in vitro JCT model using a polycaprolactone nanofibrous scaffold, which could recapitulate the functional JCT morphology and study the flow of aqueous humor. The model exhibited HTM-like characteristics and allowed for investigation of the relationship between aqueous humor outflow and HTM degeneration as well as drug screening.
Primary open-angle glaucoma is characterized by the progressive degeneration of the optic nerve, with the high intraocular pressure (IOP) being one of the main risk factors. The human trabecular meshwork (HTM), specifically the juxtacanalicular tissue (JCT), is responsible for placing resistance to the aqueous humor (AH) outflow and the resulting IOP control. Currently, the lack of a proper in vitro JCT model and the complexity of three-dimensional models impede advances in understanding the relationship between AH outflow and HTM degeneration. Therefore, we design an in vitro JCT model using a polycaprolactone (PCL) nanofibrous scaffold, which supports cells to recapitulate the functional JCT morphology and allow the study of outflow physiology. Mechanical and morphological characterizations of the electrospun membranes were performed, and human trabecular meshwork cells were seeded over the scaffolds. The engineered JCT was characterized by scanning electron microscopy, quantitative real-time polymerase chain reaction, and immunochemistry assays staining HTM cell markers and proteins. A pressure-sensitive perfusion system was constructed and used for the investigation of the outflow facility of the polymeric scaffold treated with dexamethasone (a glucocorticoid) and netarsudil (a novel IOP lowering the rho inhibitor). Cells in the in vitro model exhibited an HTM-like morphology, expression of myocilin, fibronectin, and collagen IV, genetic expression, outflow characteristics, and drug responsiveness. Altogether, the present work develops an in vitro JCT model to better understand HTM cell biology and the relationship between the AH outflow and the HTM and allow further drug screening of pharmacological agents that affect the trabecular outflow facility.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available